Does thrombolytic therapy have a place in the treatment of pulmonary embolism after the acute stage?
D012103:Batroxobin / Q000627:therapeutic use; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005340:Fibrinogen / Q000378:metabolism; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006493:Heparin / Q000627:therapeutic use; D006801:Humans; D010958:Plasminogen / Q000627:therapeutic use; D011655:Pulmonary Embolism / Q000188:drug therapy*; D014568:Urokinase-Type Plasminogen Activator / Q000627:therapeutic use
D005343:Fibrinolytic Agents; D005340:Fibrinogen; D010958:Plasminogen; D006493:Heparin; D012103:Batroxobin; D014568:Urokinase-Type Plasminogen Activator